Latest Stories
Guest Editorial
Rick Pazdur, MD, the newly appointed director for the Center for Drug Evaluation and Research at the FDA, has been described as “greyhound thin” as a result of his dedication to cycling and lifting weights in the gym each day and, for a long time, a vegetarian diet. I first met him when he was the director of the Office of Oncology Drug Products (ODP) within CDER, in 2009.
Guest Editorial
To say that it has been an eventful few months for George Tidmarsh would be a bit of an understatement.
ClinicalTrials & Tribulations
At the recent ASCO annual meeting, within hematologic malignancies, therapies for multiple myeloma stole the show, comme d’habitude.
Book Review
E. Donnall Thomas, the Nobel Prize-winning pioneer of bone marrow transplantation, liked to make the point that his life spanned the period of time from when physicians like his own father still made house calls in a horse and buggy, to when T-cells were genetically engineered to be used therapeutically.
Guest Editorial
Over and over again, I’ve seen the same missteps, clumsy excuses, and faulty logic during sponsor presentations to the FDA Oncologic Drugs Advisory Committee, repeated as if part of a tragic, regulatory update to the movie Groundhog Day.
